Substance P restores spermatogenesis in busulfan-treated mice: A new strategy for male infertility therapy - 19/12/20
pages | 10 |
Iconographies | 11 |
Vidéos | 0 |
Autres | 0 |
Graphical abstract |
Highlights |
• | Substance P administration significantly restores spermatogenesis in busulfan induced non-obstructive azoospermic mice. |
• | Substance P promotes spermatogonia proliferation via activating MAPK/Erk signaling pathway. |
• | Substance P exerts therapeutic effects on spermatogenesis through binding to NK1R. |
Abstract |
Male infertility has become an important health problem that is primarily caused by testicular dysfunction with abnormal spermatogenesis. In this study, we demonstrated that the neuropeptide, substance P (SP), is essential for spermatogonia proliferation in a seminiferous tubule culture system. In addition, SP (5 nmol/kg) treatment markedly restored spermatogenesis, improved sperm quality, and increased the number of ZBTB16+ or LIN28+ undifferentiated spermatogonia as well as STRA8+ differentiated spermatogonia in a busulfan-induced non-obstructive azoospermic mouse model. Furthermore, 100 nM SP treatment in vitro significantly stimulated the proliferation of GC-1 spg cells (a spermatogonia cell line) via activation of the Erk1/2 signaling pathway. Moreover, the sperm quality and the number of spermatogonia were significantly reduced after treatment with RP67580, a selective NK-1 receptor antagonist, suggesting that SP-NK1R signaling plays an important role in spermatogenesis. Taken together, these results suggest that SP may be a potential therapeutic agent for male infertility by accelerating the restoration of spermatogenesis.
Le texte complet de cet article est disponible en PDF.Abbreviations : SP, Bus, SSCs, NK1R, NOA, DDX4, ZBTB16, STRA8, Bcl6b, Gfra1, Nanos3, Kit, Spo11
Keywords : Spermatogenesis, Substance P, Male infertility, Endogenous spermatogonia
Plan
Vol 133
Article 110868- janvier 2021 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?